Hiroki Sugita



Hiroki Sugita is a partner in Orrick’s Tokyo Office and a member of the M&A and Private Equity Group. He works on a wide range of cross-border transactions including mergers and acquisitions, joint ventures, emerging companies and venture capital transactions, and private equity investment especially in Japan, the United States, Europe and Asia.

He also has extensive experience in fund formation, real estate and various types of finance transactions.

Hiroki has a deep understanding of clients’ needs from his secondment experience with a U.S. investment bank in 2005 and a Japanese major trading house from 2012 to 2014.

Prior to joining Orrick, Hiroki worked at O’Melveny’s Tokyo office as a counsel where he mainly worked on cross border M&A.

  • Mergers and Acquisitions (Cross-border)

    • Representation of a Japanes biopharmaceutical company the JPY65 billion acquisition of Swiss pharmaceuticals business in Japan and APAC.
    • Representation of a Japanese cryptocurrency exchange company on its sale to a crypto derivative exchange company.
    • Representation of a Japanese chemical company in its acquisition of 45% stakes in a leading Japanese manufacturer of specialty chemicals, from a U.S.-based global technology and specialty material company.
    • Representation of a Japanese developer and manufacturer of medical devices in its 50% share acquisition of a regulatory, clinical and reimbursement consultancy in Japan.
    • Advised a Japanese chemical company in an agreement to acquire the plant health business from a global animal health company.
    • Representation of a Japanese chemical manufacturer in the acquisition of a German insulation systems manufacturer.
    • Representation of food products manufacturer in Japan in its agreement with a major producer and seller of chemical products, and a company that imports and sells infant formula, both from Asia to form a joint venture for producing and selling powdered infant formula in Asia.
    • Representation of a U.S. investment bank in its acquisition of a golf course redevelopment project in Japan.
    • Representation of a leading U.S. manufacturer of high-performance semiconductors in the acquisition of a high-performance filter business from Panasonic Corporation, through corporate separation.
    • Representation of a leading U.S. manufacturer and supplier of electronic components, in the acquisition of a Japanese electronic parts company.
    • Representation of a major Japanese trading firm, in the investment in an Indonesia-based high-speed network company.
    • Representation of a Japanese information and communication technology service provider and a Japanese trading firm, in their investment in an Indonesia-based data center company.
    • Representation of a leading hard drive manufacturer in its $4.8B acquisition of a Japanese hard disk drive manufacturer.
    • Representation of a Japan based online game company in its acquisition of various online game content companies.
    • Representation of a global food and beverage producer based in Japan in its acquisition of allergy-oriented, hypoallergenic nutritional supplement company through a public tender offer.
    • Representation of a Japan based electronic and electronics equipment manufacturer in its acquisition of a Japan subsidiary of a U.S. based electronic and electrical interconnect system supplier.

    Private Equity and Venture Capital (Cross-border)

    • Representation of a Japanese multinational automotive manufacturer on its US$400 million investment into an autonomous vehicle technology company co-located in the United States and China.
    • Representation of a financial service company in their investment of a Massachusetts based company that developed small molecule drugs intended to activate progenitor cells within the body to restore and regenerate tissues.
    • Representation of a cryptocurrency exchange company, the second “unicorn” in Japan’s startup space, in their Series C funding.
    • Representation of major Japanese general trading company in the establishment of a corporate venture capital fund with a California-based venture capital firm.
    • Representation of a Japanese company targeting innovations in oncology, CNS and autoimmune disease, in their US$4.9 million Series A financing.
    • Representation of the largest Japan-based manufacturer of cranes in its LP investment in a US venture fund.
    • Representation of a startup developing AI learning in virtual space, in raising over JPY 2 billion from domestic and foreign investors.
    • Representation of a Tokyo based start-up on its pre-A round of US$3 million.
    • Assisted in the formation of a fund with a JPY 10 billion target to invest in unlisted venture companies in Japan and overseas, mainly in the bio-healthcare and numerous following investments, as part of the first project for the "Global alliance Promotion Scheme" advocated by the Ministry of Economy, Trade and Industry in Japan.
    • Representation of a venture capital fund in their investment in a Japanese pharmaceutical company for their Series A round.
    • Representation of a French venture company in their JPY 1.45 billion investment into a Japan-based pharmaceutical venture company.
    • Representation of a Japan-based travel agency in their strategic B investment in a Taiwanese online travel start up.
    • Representation of a venture company in its investment into the US$7.3 million Series A round for a Japanese developer of a cloud-based satellite-antenna sharing platform.
    • Representation of a Japanese trading firm in its strategic investment into a leading U.S. cross-device identity management technology startup.
    • Representation of a Japan and Silicon Valley based deep-learning fintech company in its sale of an image web service, and in its $1.7 million seed financing.
    • Representation of a Japanese trading firm in venture investment in a China-based drug research and development company.
    • Representation of a Japanese trading firm in investment in a China-based energy storage company.
    • Representation of a U.S.-based venture capital in its series B investment into a Japanese IoT company.
    • Representation of a Japanese trading firm in its investment in a Chinese fund.
    • Representation of Coller Capital in its investment in Pfizer Japan’s spin-off company through subscription of shares and warrants
    • Representation of foreign sovereign fund in its investment in a licensed securities company in Japan through convertible preferred stock subscription.